Study of the Safety and Efficacy of REGN475 in Patients With Pain Resulting From Thermal Injury.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2011
At a glance
- Drugs Fasinumab (Primary)
- Indications Pain
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 09 Jul 2010 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 28 Jan 2010 New trial record